In June 2007 Medimmune Inc was acquired by AstraZeneca. MedImmune develops drugs for transplants and infectious diseases. Its product-development strategy emphasizes prevention over treatment. Products include CytoGam, which prevents and treats cytomegalovirus disease in organ transplant patients, and RespiGam (an intravenous treatment ), which prevents respiratory syncytial virus (RSV), a leading cause of pneumonia and bronchiolitis in infants. MedImmune has received FDA approval to market Synagis (an injectable treatment for RSV). Products in development include vaccines to prevent genital warts, cervical cancer, Lyme disease, urinary tract infections, and organ transplant rejection. The firm is buying U.S. Bioscience to move into the oncology drug market. Manufactures the vaccine nasal spray FluMist(tm)
